All News

If approved, this combination will become a first-line treatment option for patients who are cisplatin eligible.

The aim of developing GP40141 as a biosimilar is to help reduce the cost of the drug and make treatment more affordable for those with idiopathic thrombocytopenic purpura, according to investigators.

Non-expansion states had an increase in prescriptions after PA removal at 27.3% and Medicaid expansion states demonstrated a 22% decrease in prescriptions.

According to the authors, current HIV care methods demonstrate that the mean age at death for Black MSM was 68.8 years, whereas the mean age for White MSM was 75.6 years.

Following acoustic stimulation intervention, many patients experienced a reduction in neurobehavioral symptoms.

Investigators believe lowering cholesteryl ester levels could help prevent brain damage and behavioral changes, reducing the risk of Alzheimer disease.

Although involvement of a cardiologist for heart failure has been associated with reduced rates of in-hospital mortality, not all patients see a cardiologist when hospitalized, according to the investigators.

Many workers don’t advertise their level of loneliness, nor do they know the impact of loneliness on their well-being.

Exclusions of medication are often focused on high-cost specialty formularies, resulting in fewer options for patients who need them.

Marlo Blazer, PharmD, BCOP, discusses the collaborative nature of the pharmacist's role within the oncology care team.

An animal study shows that early-life stress may increase risk-taking behaviors in adulthood; in humans, this could translate to risk of substance use disorder.

Patients with uncontrolled chronic obstructive pulmonary disease and type 2 inflammation had significantly better lung function at least a year into dupilumab regimen.

Nacre may combat cortical bone loss and improve bone strength to reduce risk of fragility fractures.

These findings could make a significant difference in treating patients with Barth syndrome, which is an incurable genetic disease.

Neuroimaging showed that people who lacked sleep had altered risk-taking behaviors.

With wider testing available, diagnosing COVID-19 has become easier and many patients now have access to important treatment options.

There is a great need to protect families and children that are commercially insured following the COVID-19 pandemic.

Further research is necessary to better understand the development and factors that contribute to CBC after PBC treatment.

Drug reaction with eosinophilia and systemic symptoms can start as a rash and quickly progress, affecting the internal organs and requiring hospitalization, even resulting in death.

Melatonin is not fully regulated by the FDA, and there are concerns about children taking the supplement due to associated risks, such as dependency and overdose.

By strengthening the continent's health care infrastructure, promoting local vaccine production, and facilitating global collaborations, the grant represents an important milestone toward better health care for all Africans.

Patients hospitalized for traumatic brain injury have different brain injury biomarkers and rates of glucose variation.

This is KRP203’s second Orphan Drug Designation and it is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers.

This innovation could be useful for optimizing the collaboration between patients with asthma and their health care providers through remote telemedicine consultations.

The study authors are encouraged by the findings, noting that LIMS with algorithmic-based classification can aid in early and accurate diagnosis of skin cancer, improving patient prognosis.

No significant demographic or phenotypic differences were found between HLA-DQA1*05 carriers versus non-carriers, in either treatment group.

In addition to predicting breast cancer outcomes, the AI tool can help determine effective treatment options in patients, sparing them from unnecessary treatments.

Individuals treated with remibrutinib demonstrated symptom control improvement in week 2 of the trial

Belantamab mafodotin (Blenrep; GlaxoSmithKline) demonstrated that, when combined with bortezomib and dexamethasone (BorDex), the time to disease progression or death was extended.

This FDA clearance comes about 11 months after another clearance for appliances to treat mild-to-moderate obstructive sleep apnea (OSA)—the first clearance for oral appliances to treat OSA with supplemental therapies.